SAN FRANCISCO, Nov. 12, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a clinical stage biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced that results from a Phase 2 gastric cancer trial of telatinib on biomarker response will be presented at the AACR-NCI-EORTC International Conference in San Francisco. The results demonstrate that patients who were treated with a combination regimen of telatinib, a potent and selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR), capecitabine and cisplatin and who responded with a large decrease of a specific angiogenesis biomarker - the soluble form of VEGFR2 (sVEGFR2) - were found to have a lower risk of disease progression and death compared to patients with smaller decreases.
